Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

[1]  J. Bourhis,et al.  Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. , 2011, Blood.

[2]  H. Dombret,et al.  Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study , 2010, Cancer.

[3]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[4]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Bourhis,et al.  Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group , 2007, Leukemia.

[6]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[7]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[8]  C. Craddock,et al.  Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Kantarjian,et al.  Outcome of patients with acute myelogenous leukemia after second salvage therapy , 2005, Cancer.

[10]  C. Craddock,et al.  Biology and management of relapsed acute myeloid leukaemia , 2005, British journal of haematology.

[11]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Dombret,et al.  Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. , 2004, Blood.

[13]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[14]  A. Nademanee,et al.  A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Bob Löwenberg,et al.  Acute myeloid leukemia and acute promyelocytic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.

[16]  N Keiding,et al.  Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis , 2001, Bone Marrow Transplantation.

[17]  A. Baruchel,et al.  Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM) , 2000, Bone Marrow Transplantation.

[18]  E. Estey.  Treatment of relapsed and refractory acute myelogenous leukemia , 2000, Leukemia.

[19]  C. Bloomfield,et al.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[21]  S. Davies,et al.  Feasibility and timing of unrelated donor identification for patients with ALL. , 1996, Bone marrow transplantation.

[22]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[23]  S. Feig,et al.  Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors , 1994, British journal of haematology.

[24]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[25]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[26]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[27]  D. Catovsky,et al.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.